Search results
15 sie 2024 · The imposed MFP for a 30-day equivalent supply of ELIQUIS, which is the price that Medicare will pay for ELIQUIS as of January 1, 2026, is $231.00.
15 sie 2024 · Today, the U.S. Department of Health and Human Services released the “Maximum Fair Price” (MFP) for a 30-day supply of ELIQUIS® (apixaban), which was selected in the first round of government price setting as part of the Inflation Reduction Act (IRA).
On August 15, 2024, pursuant to the Inflation Reduction Act of 2022 (“IRA”), the U.S. Department of Health and Human Services released the “maximum fair price” (“MFP”) for a 30-day equivalent supply of Eliquis (apixaban) of $231 which applies to the U.S. Medicare channel.
31 sty 2024 · Generic apixaban has been recommended by NHS England over the previous first choice, edoxaban (Lixiana; Daiichi Sankyo), as a preferred direct-acting oral anticoagulant (DOAC) for the treatment of atrial fibrillation (AF) in new patients.
15 sie 2024 · Here are the negotiated prices for the drugs, based on a 30-day supply: Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price....
By 2030, up to 80 drugs will have lower negotiated prices. One of the first ten drugs selected for negotiation is Eliquis, a drug used to treat blood clots, manufactured by Bristol Myers Squibb and Pfizer.
Starting in 2024, the law expands the Extra Help program, which makes premiums and copays more affordable for people with limited resources with Medicare prescription drug coverage. And in 2025, the new $2,000 maximum out-of-pocket cap will provide additional help to those enrolled in a Medicare Part D plan.
